The FDA approved the oral Wegovy pill for those favoring a non-injectable option in December 2025
While tirzepatide is not associated with nightmares in FDA labeling or clinical trials, it's worth noting that nocturnal hypoglycemia can cause nightmares, night sweats, and sleep disturbances
PlexusDx does not sell, prescribe, or recommend any other therapeutic peptide in the GLP-1 category beyond semaglutide and tirzepatide (including dulaglutide, liraglutide, retatrutide, cagrilintide, and related compounds)
Understanding realistic expectations and the factors that influence outcomes helps patients and healthcare providers optimize this medication as part of a comprehensive weight management program
A 2.0 mg dose was approved in 2024 for additional glycaemic control